These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16429296)

  • 41. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
    Garbino J; Villiger P; Caviezel A; Matulionyte R; Uckay I; Morel P; Lew D
    Infection; 2007 Jun; 35(3):161-6. PubMed ID: 17565457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections.
    Kreter B
    Clin Ther; 1992; 14(1):110-21. PubMed ID: 1576620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
    Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
    Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imipenem/cilastatin therapy for serious infections in neonates and infants.
    Nalin DR; Jacobsen CA
    Scand J Infect Dis Suppl; 1987; 52():46-55. PubMed ID: 3331042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F; Wu G; Zheng B
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
    Marra FO; Frighetto LO; Marra CA; Sleigh KM; Stiver HG; Bryce EA; Reynolds RP; Jewesson PJ
    Ann Pharmacother; 1999 Feb; 33(2):156-62. PubMed ID: 10084409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
    Infection; 1996; 24(6):480-4. PubMed ID: 9007599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G; Cravarezza P
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meropenem. A pharmacoeconomic review of its use in serious infections.
    Holliday SM; Benfield P
    Pharmacoeconomics; 1998 Mar; 13(3):359-77. PubMed ID: 10178661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
    Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P
    Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.
    Tori K; Tansarli GS; Parente DM; Kalligeros M; Ziakas PD; Mylonakis E
    Medicine (Baltimore); 2020 May; 99(20):e20022. PubMed ID: 32443305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Imipenem/cilastatin in surgical intensive medicine].
    Wenk H; Schier H; Hollandt H; Valesky A
    Infection; 1986; 14 Suppl 2():S171-5. PubMed ID: 3759252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.
    Norrby SR; Eriksson M; Ottosson E
    Scand J Infect Dis; 1986; 18(4):371-4. PubMed ID: 3094139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [An imipenem-cilastatin combination in the treatment of infection at general intensive care units].
    Gouin F
    Presse Med; 1990 Apr; 19(13):620-4. PubMed ID: 2139943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meropenem: a review of its use in the treatment of serious bacterial infections.
    Baldwin CM; Lyseng-Williamson KA; Keam SJ
    Drugs; 2008; 68(6):803-38. PubMed ID: 18416587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imipenem/cilastatin: its use in the treatment of foot infections in the compromised host.
    Ross CD; Pantig-Felix L; Kanat IO
    J Am Podiatr Med Assoc; 1988 Jul; 78(7):361-7. PubMed ID: 3042952
    [No Abstract]   [Full Text] [Related]  

  • 59. Meropenem: a review of its use in patients in intensive care.
    Hurst M; Lamb HM
    Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management and prevention of diabetic foot ulcers and infections: a health economic review.
    Chow I; Lemos EV; Einarson TR
    Pharmacoeconomics; 2008; 26(12):1019-35. PubMed ID: 19014203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.